Novo Nordisk Faces Crosswinds: EU Approvals and Heart Data Offset Brazil Generic Threat and Pricing Pressure

Novo Nordisk stock near €38 as Brazil OKs generic Ozempic, EU clears 2 Wegovy variants, CV study shows residual inflammation, complicating case.

Novo Nordisk’s stock remains stuck at around €38, a far cry from the €70-plus peak touched in the past year, as the company wrestles with conflicting signals across its key markets. The latest developments — a first generic approval for Ozempic in Brazil, two new Wegovy variants cleared by European regulators, and a large-scale cardiovascular study presented in Athens — underscore the complexity of the investment case. The shares have shed roughly 15% since January, and the pressure shows no sign of easing.

Brazil has become the latest frontier for generic semaglutide after the local regulator gave the green light to a copycat version of Ozempic. The country’s GLP-1 market was worth $188 million in 2024 and is forecast to exceed $530 million by 2030, making it one of the fastest-growing outlets for the class. Domestic manufacturer EMS has ploughed more than 1 billion reais into its own peptide production and rolled out its first GLP-1 pen last August. Brazil now joins India, Canada and China in permitting generic semaglutide entry. Novo Nordisk’s U.S. patent protection for Ozempic, by contrast, remains intact until at least 2031–2032.

Offsetting that blow, the European Medicines Agency’s human medicines committee recommended two new Wegovy formulations on 22 and 23 May. The daily 25-milligram oral tablet — the only GLP-1 pill without interaction restrictions on its label — has already drawn more than one million patients in the U.S. within four months of launch. Novo Nordisk plans to roll it out in selected markets outside the U.S. in the second half of 2026. The second approval covers a high-dose single-use pen delivering 7.2 milligrams weekly, replacing three separate 2.4 mg injections. In the STEP-UP trial, obese patients achieved a mean weight loss of 20.7%, with roughly one in three shedding more than a quarter of their body weight. For patients with both obesity and type 2 diabetes, the mean reduction was 14.1%. The EU launch of the high-dose pen is pegged for the third quarter of 2026.

Meanwhile, Novo Nordisk used the European Atherosclerosis Society congress in Athens to broaden its scientific narrative beyond weight loss. The POSEIDON observational study tracked nearly 19,000 patients across 18 countries between 2023 and 2025, making it one of the largest global analyses of cardiovascular inflammation in high-risk populations. The headline finding: two in five patients with atherosclerotic cardiovascular disease and chronic kidney disease, and a similar proportion of heart failure patients, showed elevated inflammation, measured as high-sensitivity C-reactive protein of at least 2 mg/L. The company argues that even optimal guideline-based therapy fails to eliminate this residual risk, positioning its pipeline as a potential solution across the cardiometabolic spectrum.

For investors, the data are less a near-term revenue catalyst than a reminder of Novo Nordisk’s long-term ambition to be seen as a broad cardiometabolic player rather than a pure-play weight-loss company. Whether that scientific positioning translates into new development programmes or commercial opportunities remains an open question. The market reaction was muted: the stock slipped roughly 0.5% on the day of the presentation.

The operational picture remains dominated by GLP-1 products. In the first quarter of 2026, reported sales rose 32% in constant currencies, but that figure was flattered by a one-off adjustment linked to the U.S. 340B drug-pricing programme. Stripping out that effect, revenue fell 4%, while the obesity segment alone grew 22% on an adjusted basis. Adjusted operating profit declined 6% to about 32.9 billion Danish kroner. The company now guides for adjusted sales and operating profit to contract between 4% and 12% in constant currencies for the full year — a range that reflects lower realised prices, reduced Medicaid reimbursement for obesity treatments, and the impact of the U.S. “Most Favoured Nations” pricing rule.

Novo Nordisk still commands roughly 55% of the weekly injectable GLP-1 market and sells Wegovy in more than 55 countries. But the margin for error is shrinking. The Brazilian generic approval accelerates the competitive pressure already building from copycat drugs in other emerging economies, while the pricing headwinds in the U.S. show no sign of abating. The two European approvals offer a counterweight, but their commercial contributions will only begin to materialise in the second half of 2026 and beyond.

The next clear checkpoint for the story will come with the half-year results in August, when investors will see whether the EU-backed launches and the POSEIDON narrative can offset the growing weight of generics and pricing constraints. For now, the stock’s trajectory reflects a market that is still trying to reconcile a strong therapeutic franchise with a deteriorating short-term financial outlook.